{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:58Z","timestamp":1785545038206,"version":"3.56.0"},"reference-count":28,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Diabetic peripheral neuropathy (DPN) is a length-dependent, symmetric sensorimotor polyneuropathy with a substantial global and regional burden. Current pharmacologic options are largely symptomatic and do not modify the disease. Lymphovenous bypass (LVB), a supermicrosurgical procedure established for lymphedema, may modulate lymphatic-immune-microvascular dysfunction relevant to DPN.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The primary objective is to determine whether LVB combined with standard of care (SOC) improves small-fiber and autonomic function compared with SOC alone at 6 months. Secondary objectives are to evaluate the effects of LVB on large-fiber function, neuropathic pain, ulcer healing, quality of life, and relevant biomarkers, as well as to characterize the safety profile of LVB.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This is a SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials)\u2013aligned, single-center, randomized, controlled, parallel-group superiority trial with a 2:1 allocation (LVB+SOC vs SOC alone). Randomization is stratified based on the presence or absence of active diabetic foot ulcers, as defined by the International Working Group on the Diabetic Foot and Infectious Diseases Society of America criteria. In total, 60 adults aged 20 to 80 years with confirmed DPN will be enrolled. LVB involves lymphatic-venous anastomosis to venules \u22640.8 mm. SOC consists of guideline-based glycemic and risk-factor management, pain control, and standardized wound care. Outcome assessors and statisticians are blinded. The primary outcomes are changes in clinical neuropathy burden and pain severity at 6 and 12 months. Secondary outcomes comprise objective measures of somatic and autonomic physiology, histopathological nerve fiber density, biological serum markers, and longitudinal ulcer epithelialization parameters. Data analysis will use mixed-effects models for repeated measures, with a sample size of 60 adults providing 80% power to detect a conservative between-group effect size of Cohen\n d<\/jats:italic>\n =0.70.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Recruitment commenced in February 2026 and is planned to continue through July 31, 2027, with follow-up through July 31, 2028. As of May 2026, we have enrolled 3 participants. The first participant has been treated, and a second participant is scheduled to undergo treatment. Data analysis and reporting are anticipated between late 2027 and early 2028. No outcome data are included.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This trial tests a mechanism-based, nonpharmacologic adjunct targeting lymphatic-immune-microvascular dysfunction in DPN. If effective, LVB could inform phenotype-directed treatment algorithms and motivate multicenter evaluation and health economic analyses.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/84826","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:50:05Z","timestamp":1779137405000},"page":"e84826-e84826","source":"Crossref","is-referenced-by-count":0,"title":["Lymphovenous Bypass as an Adjunct to Standard Care for Diabetic Peripheral Neuropathy: Protocol for a Randomized Assessor-Blinded Superiority Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7900-4800","authenticated-orcid":false,"given":"Hsin-Ying","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-3935","authenticated-orcid":false,"given":"Chih-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-5847","authenticated-orcid":false,"given":"Tien-Jyun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-5789","authenticated-orcid":false,"given":"Chi-Chao","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-8482","authenticated-orcid":false,"given":"Sung-Tsang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4071-5628","authenticated-orcid":false,"given":"Nai-Chen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-0494","authenticated-orcid":false,"given":"Sung-Chuan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"R1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41582-024-01041-y","article-title":"The global and regional burden of diabetic peripheral neuropathy","volume":"21","author":"Savelieff","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"R2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","article-title":"Diabetic neuropathy: clinical manifestations and current treatments","volume":"11","author":"Callaghan","journal-title":"Lancet Neurol"},{"issue":"1","key":"R3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","journal-title":"Diabetes Care"},{"issue":"7","key":"R4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41574-021-00496-z","article-title":"Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy","volume":"17","author":"Sloan","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"R5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209652","article-title":"Development and progression of polyneuropathy over 5 years in patients with type 2 diabetes","volume":"103","author":"Brask-Thomsen","journal-title":"Neurology"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000085306","article-title":"Two-stage community-based screening model for estimating prevalence of diabetic polyneuropathy (KCIS no. 6)","volume":"25","author":"Hsu","journal-title":"Neuroepidemiology"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-89","article-title":"Insufficient early detection of peripheral neurovasculopathy and associated factors in rural diabetes residents of Taiwan: a cross-sectional study","volume":"14","author":"Lee","journal-title":"BMC Endocr Disord"},{"issue":"42","key":"R8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001783","article-title":"Cardiovascular risk factors increase the risks of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: the Taiwan Diabetes Study","volume":"94","author":"Yang","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"R9","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S2213-8587(19)30081-6","article-title":"Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention","volume":"7","author":"Selvarajah","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1155\/jdr\/5902036","article-title":"Diagnostic accuracy of screening tests for diabetic peripheral neuropathy: an umbrella review","volume":"2024","author":"Mogilevskaya","journal-title":"J Diabetes Res"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2024.1454095","article-title":"From Sudoscan to bedside: theory, modalities, and application of electrochemical skin conductance in medical diagnostics","volume":"18","author":"Vittrant","journal-title":"Front Neuroanat"},{"issue":"2","key":"R12","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.neucli.2023.102859","article-title":"The value of electrochemical skin conductance measurement by Sudoscan\u00ae for assessing autonomic dysfunction in peripheral neuropathies beyond diabetes","volume":"53","author":"Lefaucheur","journal-title":"Neurophysiol Clin"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S442595","article-title":"Update on treating painful diabetic peripheral neuropathy: a review of current US guidelines with a focus on the most recently approved management options","volume":"17","author":"Mallick-Searle","journal-title":"J Pain Res"},{"issue":"1","key":"R14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040622314552071","article-title":"Treatment of painful diabetic neuropathy","volume":"6","author":"Javed","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"R15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","article-title":"Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy","volume":"67","author":"Dhanapalaratnam","journal-title":"Diabetologia"},{"issue":"23","key":"R16","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1136\/heartjnl-2018-314461","article-title":"Role of the lymphatic vasculature in cardiovascular medicine","volume":"105","author":"Telinius","journal-title":"Heart"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1161\/CIRCRESAHA.115.306544","article-title":"Lymphatic system in cardiovascular medicine","volume":"118","author":"Aspelund","journal-title":"Circ Res"},{"issue":"6","key":"R18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamasurg.2020.0015","article-title":"Surgical treatment of lymphedema","volume":"155","author":"Ogunleye","journal-title":"JAMA Surg"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/PRS.0000000000005993","article-title":"Surgical treatment of lymphedema","volume":"144","author":"Schaverien","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"R20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1089\/wound.2018.0871","article-title":"Lymphovenous anastomosis aids wound healing in lymphedema: relationship between lymphedema and delayed wound healing from a view of immune mechanisms","volume":"8","author":"Yoshida","journal-title":"Adv Wound Care (New Rochelle)"},{"issue":"7","key":"R21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071540","article-title":"Lymphaticovenous anastomosis supermicrosurgery decreases oxidative stress and increases antioxidant capacity in the serum of lymphedema patients","volume":"10","author":"Yang","journal-title":"J Clin Med"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S350421","article-title":"Recovery of dysregulated genes in cancer-related lower limb lymphedema after supermicrosurgical lymphaticovenous anastomosis \u2013 a prospective longitudinal cohort study","volume":"15","author":"Yang","journal-title":"J Inflamm Res"},{"issue":"8","key":"R23","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000006064","article-title":"Lymphovenous bypass as an alternative strategy for managing phleboedema and venous leg ulcers: preliminary results","volume":"12","author":"Chao","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"6","key":"R24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/SLA.0000000000004061","article-title":"Anaphylactic reaction rates to blue dyes used for sentinel lymph node mapping: systematic review and meta-analysis","volume":"273","author":"Perenyei","journal-title":"Ann Surg"},{"issue":"11","key":"R25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15111311","article-title":"Intraepidermal nerve fiber density as an indicator of neuropathy predisposition: a systematic review with meta-analysis","volume":"15","author":"Samolis","journal-title":"Diagnostics (Basel)"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1161077","article-title":"Abnormal intraepidermal nerve fiber density in disease: a scoping review","volume":"14","author":"Thomas","journal-title":"Front Neurol"},{"issue":"2","key":"R27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clinthera.2021.12.002","article-title":"Diabetic foot ulcers and cardiac autonomic neuropathy","volume":"44","author":"Basra","journal-title":"Clin Ther"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.709114","article-title":"Peripheral nerve conduction and sympathetic skin response are reliable methods to detect diabetic cardiac autonomic neuropathy","volume":"12","author":"Lin","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e84826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:25:55Z","timestamp":1785536755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e84826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2196\/84826","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"v15i1e84826"}}